$CBRS

Cerebras (NASDAQ: CBRS), an AI chipmaker, saw its stock drop 52% since its May IPO. Analysts remain bullish, with a median price target of $295, double its current price. The decline followed a shift to cloud services and concerns about OpenAI's use of Nvidia GPUs. Cerebras has a $25.4B backlog, primarily from OpenAI, but faces execution risks in its new business model.

CIBC plans to list 11 new U.S. Canadian Depositary Receipts (CDRs) on the TSX, starting October 20, 2026, expanding its offering to 144 CDRs. These CDRs represent well-known U.S. companies and provide Canadian investors with access to global stocks in Canadian dollars, with a built-in currency hedge. The new CDRs include companies like Bloom Energy, Bristol-Myers Squibb, and Snowflake.

Ark Invest, led by Cathie Wood, bought 22,734 shares of Meta (META) and 67,362 shares of Cerebras (CBRS), while selling 3,465 shares of Alibaba (BABA). Meta's CEO Mark Zuckerberg discussed potential $100B-$200B AI investments. Cerebras faces potential selling pressure from IPO lock-up expirations. Alibaba's rally followed speculation of state-backed market intervention.

Cerebras Systems (CBRS) has $25.4B in future revenue contracts, but its stock has fallen to a post-IPO low. The company designs AI processors, selling hardware and renting computing power. Q2 revenue grew 74% to $180.1M, with cloud services revenue up 281% to $126M. Management raised its full-year core revenue outlook to $880M-$890M. Key customers include OpenAI, Block, and AWS. Concerns about competition and customer concentration have pressured the stock.

Micron (MU), Cerebras (CBRS), SanDisk (SNDK), Meta (META), and SoundHound AI (SOUN) were among stocks drawing investor attention. Micron, SanDisk, and SK Hynix lost $108B in market value due to China's chip advancements. Cerebras fell 10.69% after a report suggested OpenAI switched to Nvidia GPUs, but rebounded partially. Meta rose 3.38% on strong AI app retention data. SoundHound AI dropped 7.79% amid tech selloff and acquisition concerns.

Cerebras Systems (CBRS) shares fell below their $185 IPO price, trading around $165 in October 2026. The AI chip designer raised $5.55B in its May 2026 IPO, debuting at $350. Revenue grew 76% in 2025 to $510M, with net income at $237.8M. Concerns include customer concentration and competition from Nvidia. Insider selling post-lockup may impact sentiment.

Cathie Wood, CEO of ARK Invest, advises investors to 'follow the agents' in AI. ARK's Q2 2026 filings show positions in Robinhood (HOOD), Coinbase (COIN), SpaceX, Cerebras (CBRS), Meta, Tesla (TSLA), and AMD (AMD). ARK reduced Robinhood shares across its ETFs, which posted Q2 revenue of $1.31B and EPS of $0.62.

SpaceX (SPCX) rose 8% after Morgan Stanley reiterated its $300 target. Nu Holdings (NU) gained 13% on Brazilian election results. Vaxcyte (PCVX) surged 57% on vaccine trial results. Schneider Electric to buy PTC (PTC) for $22.6B. Curaleaf (CURLF) raised Aurora (ACB) offer to $5/share. C.H. Robinson (CHRW) to acquire RXO (RXO) for $5.8B. Cenovus (CVE) to buy Athabasca (ATH) for C$5.7B. Gunnison Copper (GCU) pre-cleared for NYSE listing.

Stock futures dip as European debt concerns weigh on markets. Nvidia rises 0.6% on AI infrastructure spending, while Intel falls 4% amid TSMC-Terafab collaboration talks. Several companies see significant premarket moves: ALVO +8%, CBRS +4.5%, DKNG +4.6%, EL +2.8%, HOG +5.7%, PCVX +56%, PTC +36%, RXO +20%, TSM +1.6%, TXRH +2.2%, WFC +2.2%. US economic data and Fed speakers are on the calendar.

Cerebras Systems (CBRS) shares fell 19.5% to $166.43, below IPO price, down 46.5% from first-day close. Q2 revenue missed estimates, but UBS set $330 target, citing strong demand and partnerships. Analysts see 75.2% upside. Competitors NVIDIA and AMD have rallied. CBRS trades at 58.09x sales, 217x forward earnings.